tbuckley/cabot-search huggingface dataset:
AB1287 A population-based study on the prevalence and incidence of vascular primary antiphospholipid syndrome: a new rare disease
Authors: C. Nalli, L. Andreoli, G. Pascariello, A. Zentilin, E. Raffetti, G. Martini, R. Kumar, C. Gasparotti, M. Magoni, C. Scarcella, F. Donato, A. Tincani
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Antiphospholipid Syndrome (APS) is a systemic autoimmune disease characterised by the presence of thrombotic and/or obstetrical manifestations and antiphospholipid antibodies (aPL). In 2006 the updated Sapporo criteria for APS were published but by now no epidemiological study on this disease were performed. Incidence and prevalence of primary APS (PAPS) in the general population are still unknown. <h3>Objectives</h3> The aim of this study was to evaluate the prevalence during the year 2013 and incidence for the period 2011–2015 of vascular PAPS in the adult population of a defined area, Valtrompia valley, using multiple sources. Valtrompia is a 40 kilometers-long prealpine valley in northern Italy. The population in 2013 was 101.477 inhabitants. The only easy access to the valley is from Brescia, the main city of the province. This valley is a cul-de-sac area without any other comfortable and practicable access. Therefore, this valley is ideal for epidemiological studies. In addition, the only Rheumatology referral tertiary Centre of the province is located in Brescia. This project was approved by the local Ethical Committee. <h3>Methods</h3> We identified adult subjects of 18–50 years old living in Valtrompia. Patients with thrombotic events were identified by two sources: 1) hospital discharge code using keywords (deep vein thrombosis, pulmonary embolism, myocardial infarction, ischaemic stroke); 2) patients with defined diagnosis of vascular PAPS already followed by the Rheumatology tertiary Centre in Brescia. <h3>Results</h3> The prevalence of PAPS in 2013 was calculated to be 35.4 (CI 95% 20.6–59.6) per 100.000 inhabitants. Table 1 shows the incidence rates of vascular PAPS. We identified 47 patients with venous events during 2011–2015. 27/47 (57%) were tested for aPL, 4/27 (15%) positive. Regarding arterial events, 36 patients had stroke and 33/36 (92%) were tested for aPL, 4/33 (12%) positive. Finally, 64 patients with myocardial infarction (IMA): only 14/64 (22%) were tested for aPL, 2/14 (14%) positive. <b>Table 1</b> Incidence rates of antiphospholipid antibody syndrome per 100.000 inhabitants in Valtrompia in adult population (18–49 years) between 2011 and 2015. The 95% confidence intervals (CIs) are reported in parenthesis. <h3>Conclusions</h3> Preliminary results of this population-based study showed that PAPS is a rare disease. A critical point emerged from this study is that aPL were not routinely tested in young subjects with vascular events, especially in patients with myocardial infarction. The study will be implemented by contacting patients who never tested for aPL during the hospital admission. <h3>Disclosure of Interest</h3> None declared
Target of Erythropoietin, Fam210b, Regulates Erythroid Heme Synthesis By Control of Mitochondrial Iron Import and Regulation of Fech Activity
Authors: Yvette Y Yien, Jiahai Shi, Caiyong Chen, Jesmine Cheung, Anthony Grillo, Rishna Shrestha, Liangtao Li, Xuedi Zhang, Martin Daniel Kafina, Paul D. Kingsley, Matthew King, Julien Ablain, Leonard I. Zon, James Palis, Martin Burke, Daniel E. Bauer, Stuart H. Orkin, Carla Koehler, John D. Phillips, Jerry Kaplan, Diane Ward, Harvey Lodish
Journal: Blood (2018)
The relationship between overexpression of HER2 with tumor grade and 3-years overall survival of gastric cancer patients referring to Valiasr Hospital of Zanjan.
Authors: Abdolamir Feizy, Minoosh Moghimi, Pedram Fadavi, Bahman Talebipoor, Goudarz Mazdai, Shahrokh Attarian, Hadi Taheri, Reza Eghdam Zamiri
Journal: Journal of Clinical Oncology (2014)

e15050 Background: Gastric cancer is the fourth common cancer and second most common cause of cancer related death in the world and the first most common type of cancer in Zanjan Province. Despite available and common treatment methods such as surgery and chemotherapy, survival rate among patients with advanced stages of gastric cancer is low. Therefore many studies have been conducted to find new and more effective treatments among HER2 protein as a prognostic and objective factor for novel and specialized treatments has been of particular note. Therefore our study was conducted to evaluate over expression of HER2 in gastric cancer and its relation between cytopathologic parameters of the tumor and its prognostic role. Methods: This cohort retrospective study was conducted on 210 gastric cancer patients being diagnosed or treated in Valiasr hospital of Zanjan. Grades, initial location, histopathologic type of tumor and survival rate of patients were determined. Degree of HER2 expression was determined by IHC (Hercept Test) method on patients’ blocks. 36 months survival of patients in two groups (with and without HER2 expretion) was analyzed by Kaplan-Meier method and other variables by Chi square method. We cannot do Fish or Cish therefore only her2 expression as three plus positive was considered in HER2 positive group. Results: 50 cases (23.8%) were positive, 43 cases (20.5%) had no HER2 staining, there was no significant relation between HER2 over expression,grade (IHC 3+), histopathologic type, initial tumor location and patients’ survival. Conclusions: Our findings indicate that HER2 over expression has no relation with grade, histopathologic type, location and prognosis of gastric cancer. Although in many studies HER2 has role as a prognostic factor , our study shows different results due to geographical location or more likely due to difference in HER2 staining method. We suggest that in order to further investigate the reason for this difference, multi center studies or meta analysis of the findings of previous studies and using complementary more accurate methods such as FISH and CISH to study HER2 amplification is required.
Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics
Authors: Ibai Goicoechea, Noemi Puig, María Teresa Cedena, Lourdes Cordon, Maria-Belen Vidriales, Leire Burgos, Juan Flores-Montero, Norma C. Gutierrez, Maria Jose Calasanz, Maria Luisa Martin-Ramos, David Lara-Astiaso, Amaia Vilas-Zornoza, Diego Alignani, Idoia Rodriguez, Sarai Sarvide, Ramon Garcia-Sanz, Joaquin Martinez-Lopez, Albert Oriol, Rafael Rios, Jesús Martín, Rafael Martínez, Josep Sarra, Miguel T Hernández, Javier De La Rubia, Isabel Krsnik, Jose Maria Moraleda, Luis Palomera, Joan Bargay, Alberto Orfao, Laura Rosiñol, Maria-Victoria Mateos, Juan Jose Lahuerta, Joan Bladé, Jesus F San-Miguel, Bruno Paiva
Journal: Blood (2018)
Abstract 16160: Using Computational Fluid Dynamics and Imaging Registration Techniques to Identify Predictive Hemodynamic Factors of Aneurysmal Degeneration in Type B Aortic Dissection
Authors: Huijuan Xu, Bradley G Leshnower, Marina Piccinelli, Alessandro Veneziani
Journal: Circulation (2016)

Introduction: Progressive false lumen aneurysmal degeneration in type B aortic dissection (TBAD) is a complex process that is multi-factorial in etiology. Patient-specific computational fluid dynam...
Multi-Modal Mechanisms and Anti-Sickling of Novel Sulfated Non-Anticoagulant Low Molecular Weight Heparin in Sickle Cell Disease
Authors: Shaker A Mousa, Noureldien Hassan Elsayed Darwish, Vandhana Muralidharan-Chari, Mohamed Qari, Chen Qiukan, J Eric Russell, Osheiza Abdulmalik
Journal: Blood (2018)
TOP-GAN: Stain-free cancer cell classification using deep learning with a small training set
Authors: Moran Rubin, Omer Stein, Nir A. Turko, Yoav Nygate, Darina Roitshtain, Lidor Karako, Itay Barnea, Raja Giryes, Natan T. Shaked
Journal: Medical Image Analysis (2019)
Role of D-dimer in advanced cancer patients receiving end of life care.
Authors: So Yeon Oh, Sung Jae Park, In Ki Park, Ga Jin Lim, Hyun Jung Jun
Journal: Journal of Clinical Oncology (2014)

e20504 Background: The incidence of venous thromboembolism (VTE) in advanced cancer patients is high. Analysis of D-dimer concentration serves as a screening test for VTE due to its low cost and high sensitivity, although D-dimer is frequently elevated in response to other causes, such as infection or malignancy. This study aimed to evaluate the role of D-dimer in advanced cancer patients. Methods: We retrospectively reviewed medical records of patients from the Hospice and Palliative Care Center of Seoul Medical Center from July 2012 to October 2013. Incurable cancer patients exhibiting characteristics described in Well’s prediction model underwent a D-dimer test at admission. Results: Among 343 incurable cancer patients, 142 patients received a Well’s score ≥2 at admission. Only 4 patients (2.8%) had normal D-dimer levels (<0.5 μg/mL), and the majority (n=115, 81.0%) exhibited levels >2.0 μg/mL. Radiologic workups were performed for 20 patients, because VTE diagnosis would not be beneficial to patients facing imminent death. These workups confirmed VTE in 8 patients (40%). The survival time was significantly differed according to D-dimer levels with a median of 48 days (95% CI, 25.9-70.1) when D-dimer levels were <2 μg/mL and 19 days (95% CI, 13.7-24.3) days when D-dimer levels were higher (Log-rank, p<0.001). D-dimer levels were negatively correlated with survival according to Spearman’s rank correlation analysis (coefficient -0.335, p<0.001). Conclusions: In advanced cancer patients, D-dimer concentrations may lack VTE screening power as patients without VTE also exhibited high levels of D-dimer; however, these values did exhibit prognostic power in these patients.
Pledges for the new year
Authors: Elizabeth Loder
Journal: BMJ (2019)

It’s the time for a fresh set of resolutions. If one of yours is to lose or maintain weight, you might be wondering if it makes sense to use non-sugar sweeteners instead of sugar. Ingrid Toews and colleagues (doi:10.1136/bmj.k4718) conducted a systematic review and meta-analysis of the effects of non-sugar sweeteners on various health outcomes, including weight. For adults, use of non-sugar sweeteners rather than sugar was associated with small improvements in body mass index and fasting blood glucose levels. There was no evidence of beneficial effects on other outcomes, including cancer, cardiovascular disease, mood, or cognition. In the linked editorial Vasanti Malik says that the preponderance of …
Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy
Authors: Rajat Bannerji, Ranjana H. Advani, Jennifer R. Brown, Jon E. Arnason, Jeffrey A. Barnes, John N. Allan, Stephen M Ansell, Susan M. O'Brien, Julio C. Chavez, Lieve Adriaens, Melanie Ufkin, Ana Kostic, Anne Josee Paccaly, Bo Gao, Israel Lowy, David Sternberg, Max S. Topp
Journal: Blood (2017)
Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.
Authors: Volker Heinemann, Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian A. Lerchenmuller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Swantje Held, Clemens Albrecht Giessen, Andreas Jung, Thomas Kirchner, Sebastian Stintzing
Journal: Journal of Clinical Oncology (2014)

3600 Background: FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type mCRC patients. We analyzed the efficacy dependent on gender and primary tumor location within the RAS wild-type population (n=342). Methods: Primary tumor location was defined as follows: right sided CRC (RCRC): coecum to hepatic flexure; left sided CRC (LCRC): splenic flexure to rectum. Colon transversum tumors (n=9) were excluded. Differences in response (ORR) and survival (PFS/OS) within both treatment arms were calculated using two-sided Fisher´s exact and logrank test, respectively. Results: In location wise comparison LCRC shows better efficacy results (ORR, PFS and OS) when compared with RCRC especially in the cetuximab arm (Table). Female gender has a trend towards lower tumor response rates, shorter PFS and OS when compared to male patients. Conclusions: MCRC is a heterogeneous disease. Treatment efficacy depends on primary tumor location and patients' gender. Effects were more prominent in patients receiving FOLFIRI plus cetuximab where male patients with LCRC tumors are favored. FOLFIRI + Cetuximab n=167 FOLFIRI + Bevacizumab n=166 RCRC n=30 LCRC n=137 p RCRC n=39 LCRC n=127 p ORR (%) 46.7 70.1 0.019# OR: 2.7 48.7 62.2 0.14# OR: 1.7 PFS (mo) 6.9 10.8 <0.0001* HR: 0.35 8.8 10.5 0.065* HR: 0.69 OS (mo) 16.1 38.7 <0.0001* HR: 0.26 22.7 28.0 0.034* HR: 0.63 female n=44 male n=123 p male n=54 male n=112 p ORR (%) 54.5 69.9 0.095# OR: 1.9 55.6 60.7 0.61# OR: 1.24 PFS (mo) 9.2 10.6 0.005* HR: 0.60 9.1 10.3 0.051* HR: 0.70 OS (mo) 27.9 36.4 0.12* HR: 0.71 25.9 24.8 0.8* HR: 1.05 Abbreviations: Bev, bevacizumab; Cet, cetuximab; OR, Odds ratio; HR, hazard ratio; mo, months. *= logrank p; #= two-sided Fisher's exact p.
One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.
Authors: James E. Signorovitch, Eric Qiong Wu, Keith A. Betts, William M. Reichmann, Darren Thomason, Philip J Galebach, Lei Chen
Journal: Journal of Clinical Oncology (2014)

7072 Background: Nilotinib and dasatinib are BCR-ABL inhibitors that markedly differ in selectivity. In separate randomized trials, nilotinib and dasatinib have shown superior achievement of molecular response (MR) compared to imatinib for the treatment of newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (CP). In the absence of head-to-head trials, health technology assessment authorities rely on indirect comparisons to inform drug policies. This study compares MR between nilotinib 300mg twice daily and dasatinib 100mg once daily by 12 months and through 48 months via indirect comparison. Methods: Data were drawn from individual patients in the ENESTnd trial (nilotinib vs. imatinib) and published results from the DASISION trial (dasatinib vs. imatinib). Patients in ENESTnd were re-weighted to match baseline characteristics reported for DASISION (age, sex, ECOG performance status, white cell count, and platelet count) using a propensity score model. After matching, differences in major MR (MMR measured as a 3-log reduction on the International Scale [IS]), MR4.0 (4-log reduction on IS) and MR4.5(4.5-log reduction on IS) rates between nilotinib and imatinib were compared with those between dasatinib and imatinib. Cumulative MR rates through 48 months were also compared using adjusted hazard ratios (HRs) relative to imatinib. Results: After matching, rates of MR by 12 months were higher with nilotinib vs. dasatinib by 11.7% for MMR (p = 0.045), 8.2% for MR4.0 (p = 0.029), and 8.5% for MR4.5 (p < 0.001). Through 48 months of follow-up, the adjusted HR comparing MMR achievement with nilotinib vs. dasatinib was 1.44 (95% CI: 1.06, 1.94; p=0.018); the corresponding HRs for MR4.0 and MR4.5were 1.58 (95% CI: 1.10, 2.26; p=0.013) and 1.30 (95% CI: 0.86, 1.99; p=0.218), respectively. Conclusions: This indirect comparison suggested that nilotinib 300mg twice daily was associated with higher rates of achieving MMR, MR4.0, and MR4.5 by 12 months compared to dasatinib 100mg once daily for the treatment of newly diagnosed CML-CP. Higher rates of MR achievement with nilotinib were also maintained through 48 months of follow-up.
Ethnicity in mycosis fungoides: white patients present at an older age and with more advanced disease
Authors: J.J. Scarisbrick, P. Quaglino, H.M. Prince, Y.H. Kim, R. Willemze
Journal: British Journal of Dermatology (2019)

Linked Articles: Geller et al. Br J Dermatol 2019; 180:1263–1264. Scarisbrick et al. Br J Dermatol 2019; DOI: 10.1111/bjd.17258.
Analysis of Gender Equity in Leadership of Physician-Focused Medical Specialty Societies, 2008-2017
Authors: Julie K. Silver, Reem Ghalib, Julie A. Poorman, Dana Al-Assi, Sareh Parangi, Hansa Bhargava, Sasha K. Shillcutt
Journal: JAMA Internal Medicine (2019)

This cross-sectional study examines gender equity in the presidential leadership of medical specialty societies over a 10-year period.
Survival of high-grade neuroendocrine carcinomas (HGNEC) of the colon and rectum: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database.
Authors: Hammad Shafqat, Shihab Ali, Mohammed Salhab, Adam J. Olszewski
Journal: Journal of Clinical Oncology (2014)

3541 Background: HGNECs are rare, aggressive colorectal tumors, biologically similar to small cell lung cancer. Their optimal management is unclear and based on case series. Our study sought to compare survival outcomes and the role of surgery in HGNECs and high-grade adenocarcinomas (AC) using the population-based SEER registry. Methods: We obtained data on patients (pts) with colorectal HGNEC or AC diagnosed between 1998 and 2011. Relative survival (RS) was the primary endpoint. Trends in incidence and survival were calculated as annual percent change (APC). Associations with prognostic factors and treatment were analyzed in multivariate proportional hazard models, accounting for immortal time bias, and reporting hazard ratios (HR) with 95% confidence intervals (CI). Results: Compared with AC (N=392,854), HGNECs (N=1,455) were more often metastatic (18% vs. 54%, respectively) and more commonly located in the cecum or rectum, but rarely in the sigmoid (P<.0001). The incidence of HGNEC increased during the study period (APC 2.5%, P=.015), while the incidence of AC decreased (APC -3%, P<.0001). Survival was significantly worse for HGNECs than for high-grade AC at every stage (Table). No improvement over time in survival of HGNEC was seen (APC, 0.1%, P=.88), unlike in AC (APC, 0.9%, P<.0001). Stage I-III HGNECs were less likely to undergo resection (84% vs. 91% for AC, P<.0001), although the survival benefit (HR 0.50, 95% CI 0.34-0.74) was the same as for AC (P for interaction=.88). Compared with high-grade AC, resected HGNECs were more often node-positive (68% vs. 53%) or >5 cm in size (59% vs. 50%). The number of metastatic nodes was prognostic in HGNEC (HR for N2 vs. N1, 1.94, 95%CI 1.41-2.66). Conclusions: The prognosis of HGNEC has not improved over the past decade, despite advances in therapy of AC. HGNECs benefit from surgery similarly to ACs. Pts with stage I-II HGNECs have similar 5-year RS of 51%, warranting studies of adjuvant systemic therapy. High-grade AC HGNEC 5-year RS, % 95% CI 5-year RS, % 95% CI All pts 50.3 49.8-50.9 17.4 14.7-20.3 Stage I 87.8 86.0-89.4 50.5 32.0-66.4 II 77.8 76.5-78.9 51.4 34.8-66.0 III 53.3 52.5-54.2 28.6 22.4-35.1 IV 7.2 6.7-7.7 3.7 2.4-5.5
Study of AUTO3, the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22, Followed By Anti-PD1 Consolidation in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Alexander Study
Authors: Kirit Ardeshna, Maria A V Marzolini, Wendy Osborne, Muhammad Al-Hajj, Simon Thomas, Jim Faulkner, Martin Pule, Vijay G R Peddareddigari, Nushmia Z Khokhar
Journal: Blood (2018)
Further preclinical assessment of compound EL102 in the treatment of prostate cancer.
Authors: Aidan P. Toner, Francis J. Giles, Frank Sullivan, Emma Harte, Laura A. Carleton, Adrienne M. Gorman, Joe Lewis, Sharon A. Glynn
Journal: Journal of Clinical Oncology (2014)

e16053 Background: EL102 was selected from a screen of NCI-60 panel assessing growth inhibition potential. Previously, we presented findings on this toluidinesulfonamide(TS) as a candidate for prostate cancer therapy. TSs can inhibit hypoxia–inducible factor 1 alpha (HIF1-α) however the mechanism for this remains unknown. Here, we demonstrate the in vitro and in vivo effects of EL102 with regard to determining the mechanisms of HIF1-α inhibition, microtubule (MT) disruption, apoptosis induction and tumor reduction. Methods: In vitro experiments were conducted using LNCaP, DU145 and PC-3 cells. Sulforhodamine-B cytotoxicity assays determined the EL102 IC50 values of each cell line. Flow cytometry (FC) was utilized to evaluate the effects of EL102 on cell cycle. Western blot analysis of caspase-3 and PARP cleavage was done to evaluate EL102-mediated apoptosis. Immunocytofluorescence (ICF) was conducted to visualize MT stability as well as AR activation post-EL102 dosing. Downstream targets of the AR activity in LNCaP cells were assessed via western blot and qPCR analyses to determine the effects of EL102 treatments. Excised tumors from EL102-dosed CWR22 xenograft models were subjected to immunohistochemistry (IHC). Results: EL102 IC50 values of the cell lines ranged from 20-50nM. FC analyses showed an initial build-up of cells in the G2/M phase at 24 h followed by an accumulation of the subG1 population at 72 h, post-EL102 treatment. Western blot analyses suggest the accrual of subG1 cells is the product of apoptosis, while fractionation of LNCaPs shows an EL102-induced reduction in nuclear AR. ICF indicates impaired MT formation and aberrant AR activation upon EL102 exposure. Using IHC, CWR22 murine model tumors observed a marked reduction in proliferation as evidenced by a lowered Ki-67 profile, detected in those treated with EL102 versus the control cohort. Conclusions: MT destabilizing EL102 can circumvent pgp-mediated drug resistance associated with sustained taxane use in late prostate cancer. Also, EL102 inhibits HIF1α activation which may be linked to the upstream disruption of AR signaling. Moreover, tumor proliferation is reduced markedly in vivo making EL102 a prime candidate for prostate cancer treatment.
Mutant p53: A therapeutic target for the treatment of triple-negative breast cancer?
Authors: Naoise C. Synnott, Aisling Pierce, Maeve Mullooly, Francesco Caiazza, Patricia M. McGowan, Norma O'Donovan, John Crown, Michael J. Duffy
Journal: Journal of Clinical Oncology (2014)

1118 Background: Despite intensive efforts, a validated targeted therapy for triple-negative breast cancer (TNBC) remains elusive. One of the most frequent genetic alterations identified to date in TNBC is mutation in the p53 gene, which has been found in > 80% of these samples. The aim of this study was therefore to investigate mutant p53 as a potential target for the treatment of TNBC. Methods: Two compounds, PRIMA-1 and PRIMA-1METwhich have previously been shown to reactivate mutant p53 and convert it to a form with wild-type properties were investigated in a panel of 18 p53 mutant breast cancer cell lines (TNBC = 12; non-TNBC = 6). Cytoxicity was determined using the MTT assay, while induction of apoptosis was measured using both the Cell Death ELISA kit and flow cytometry. Results: Using the MTT assay, IC50 concentrations across 12 p53 mutant TNBC cell lines ranged from 1.4 to 15.1µM for PRIMA-1 and from 0.9 to 11.9 µM for PRIMA-1MET. Response to PRIMA-1 correlated significantly with that to PRIMA-1MET (p<0.0001). Inhibition of cell growth varied from 4.1 to 90.8% for PRIMA-1 and from 3.1 to 96.6% for PRIMA-1MET, using concentration of inhibitor at 6.25 µM. PRIMA-1 and PRIMA-1MET also reduced the ability of the mutant p53 cells to form colonies with IC50 values ranging from 0.16 to 10.7 μM for PRIMA-1 and from 0.02 to 9.6 μM for PRIMA-1MET. No significant difference in sensitivity for either inhibitor was observed between ER-positive and ER-negative cell lines, HER2-positive and HER2-negative cell lines or between TN and non-TN cell lines. In addition to inhibiting cell proliferation, both PRIMA-1 and PRIMA-1METalso induced apoptosis in MDA-MB-453 cells. Conclusions: Our preclinical results suggest that targeting mutant p53 with either PRIMA-1 or PRIMA-1METis a potential new approach for treating p53-mutated breast cancer including the subgroup with triple-negative disease.